艾塞那肽联合吡格列酮治疗肥胖2型糖尿病患者的疗效观察

目的观察艾塞那肽联合吡格列酮治疗肥胖2型糖尿病（T2DM）患者的疗效及安全性。方法 68例肥胖T2DM患者,在口服吡格列酮一段时间后血糖控制不理想的情况下,加用艾塞那肽,疗程3个月,观察治疗前后空腹血糖（FPG）,餐后2 h血糖（2hPG）、糖化血糖蛋白（HbA1C）、胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、C肽（C-P）、体重指数（BMI）等变化情况,计算胰岛素抵抗（H0MA-R）,胰岛β细胞功能（H0MA-β）。结果治疗后BMI、FPG、2hPG、HbA1C、HoMA-IR、TC、TG均下降;C-P,HOMA-β高于治疗前（P〈0.05）。结论艾塞那肽联合吡格列酮可显著改善肥胖T2DM患者血糖控制水平,同时能降低患者的体重,改善患者的生活质量。

The curative effect of exenatide combined pioglitazone on type 2 diabetes

Objective To observe the effect and safety of exenatide combined pioglitazone on type 2 diabetes.Methods 68 patients with type 2 diabetes who took pioglitazone for some time and still could not control the blood glucose effectively.In that case,every patient in treatment group was given exenatide for three months.The variation of the fasting blood-glucose(FPG)、 blood glucose after the meal for 2 hours(2hPG)、HbA1C、cholesterol(TC)、triglyceride(TG)、 high-density lipoprotein cholesterol(HDL-C)、low-density lipoprotein cholesterol(LDL-C)、 cpeptides(C-P) and body mass index(BMI) were observed before and after treatment.Insulin resistance(H0MA-IR)and islet β-cell function(H0MA-β) were calculate.Results After the treatment,BMI、FPG、2hPG、HbA1C、HOMA-IR、TC and TG were decreased,but C-P、HOMA-β were improved as compared with pre-treatment(P<0.05).Conclusion Exenatide combined pioglitazone could change the blood glucose of the patients with type 2 diabetes,which didn′t increase the risk of low blood glucose.It also could reduce the patient′s weight and improve the patient′s quality of life.